Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q2 FY21 Earnings Presentation
24 slides from Jubilant Pharmova's earnings presentation, Nov 4, 2020
Slide 1: Financial Results Quarter Ended September 30, 2020
Financial Results Quarter Ended September 30, 2020
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : November 04, 2020 Time : 05:00 pm IST Replay: November 04 to November 11, 2020 Dial-in: +91 22 7194 5757/ +91 22 66635757 Playback ID: 81609# 22
Slide 4: Chairmen's Message
Chairmen’s Message JUBILANT Q2’FY21 PERFORMANCE Q2’FY21 Revenue at Rs 2,375 Crore vs. Rs 2,266 Crore in Q2’FY20; Q2’FY21 EBITDA at Rs 493 Crore vs. Rs 481 Crore in Q2’FY20 Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubi
Slide 5: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, in November 2019 the Company had filed with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) the Composite Scheme of Arrangement for amalgamation of certain
Slide 6: Q2'FY21 Results Analysis
Ww Mirescncts Q2’FY21 Results Analysis
Slide 7: JLL – Q2'FY21 Financial Highlights
JLL – Q2’FY21 Financial Highlights Particulars1 Q2'FY20 Q2'FY21 YoY (%) Revenue Revenue at Rs 2,375 Crore, as compared with Rs 2,266 Crore in Pharmaceuticals 1,452 1,516 4% Q2’FY20 Life Science Ingredients 753 784 4% Drug Discovery & Development Solutions 61 75 23% • Pharmaceuticals revenue at Rs
Slide 8: Adjusted Earnings
Adjusted Earnings Consol EBITDA S. No. Particulars Q2'FY20 Q2'FY21 YoY (%) 1 Reported EBITDA 481 493 3% 2 One-off Adjustments 23 (0) 3 Adjusted EBITDA 504 493 (2%) 4 Reported EBITDA Margin 21.2% 20.8% 5 Adjusted EBITDA Margin 22.2% 20.8% One-off Expenses S. No. Particulars Q2'FY20 Q2'FY21 1 Site Rem
Slide 9: Pharmaceuticals Segment Highlights – Q2'FY21 (1/2)
Pharmaceuticals Segment Highlights – Q2’FY21 (1/2) Pharmaceuticals revenue was at Rs 1,516 Crore vs. Rs 1,452 Crore in Particulars1 Q2'FY20 Q2'FY21 YoY (%) Q2’FY20 Revenue 1,452 1,516 4% Specialty Pharmaceuticals2 Specialty Pharma 743 585 (21%) • Radiopharma business revenue was impacted due to el
Slide 10: Pharmaceuticals Segment Highlights – Q2'FY21 (2/2)
Pharmaceuticals Segment Highlights – Q2’FY21 (2/2) USFDA Inspection Details Generics1 • Revenue growth during the quarter was led by strong performance in key products Facility Last Inspection in the US market and by launch of remdesivir in various countries including India Montreal, CMO May, 2018 •
Slide 11: LSI Segment Highlights – Q2'FY21
LSI Segment Highlights – Q2’FY21 1 Particulars Q2'FY20 Q2'FY21 YoY (%) LSI revenue was at Rs 784 Crore against Rs 753 Crore in Q2’FY20. Strong Revenue 753 784 4% growth witnessed in Nutritional Products and Life Science Chemicals Specialty Intermediates 259 255 (2%) business driven by improved pri
Slide 12: Drug Discovery & Development Solutions – Q2'FY21
Drug Discovery & Development Solutions – Q2’FY21 Drug Discovery & Development Solutions (DDDS) comprises Particulars1 Q2'FY20 Q2'FY21 YoY (%) Revenue 61 75 23% • Drug Discovery Services business through Jubilant Biosys Limited Reported EBITDA 19 21 11% provides innovation and collaborative researc
Slide 13: Proprietary Novel Drugs (Jubilant Therapeutics)
Proprietary Novel Drugs (Jubilant Therapeutics) Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases, with the two lead preclinical first-in-class programs transitioning to clinic over the next 12-18 months.
Slide 14: H1'FY21 Results Analysis
H1’FY21 Results Analysis 13 13
Slide 15: JLL – H1'FY21 Financial Highlights
JLL – H1’FY21 Financial Highlights Particulars1 H1'FY20 H1'FY21 YoY (%) Revenue Revenue at Rs 4,268 Crore vs. Rs 4,448 Crore in H1’FY20 Pharmaceuticals 2,781 2,612 (6%) Life Science Ingredients 1,559 1,520 (2%) • Pharmaceuticals revenue at Rs 2,612 Crore vs. Rs 2,781 Crore in Drug Discovery & Deve
Slide 16: H1'FY21 Adjusted Earnings
H1’FY21 Adjusted Earnings Consol EBITDA S. No. Particulars H1'FY20 H1'FY21 YoY (%) 1 Reported EBITDA 925 804 (13%) 2 One-off Adjustments 57 8 3 Adjusted EBITDA 982 812 (17%) 4 Reported EBITDA Margin 20.8% 18.8% 5 Adjusted EBITDA Margin 22.1% 19.0% One-off Expenses S. No. Particulars H1'FY20 H1'FY21
Slide 17: Pharmaceuticals Segment Highlights – H1'FY21
Pharmaceuticals Segment Highlights – H1’FY21 Geography Wise Revenue1 Particulars1 H1'FY20 H1'FY21 YoY (%) Revenue 2,781 2,612 (6%) Particulars1 H1'FY20 H1'FY21 YoY (%) Specialty Pharma 1,468 1,119 (24%) India 66 113 70% North America 2,299 2,118 (8%) CDMO 756 786 4% Europe and Japan 221 222 0% Gener
Slide 18: LSI Segment Highlights – H1'FY21
LSI Segment Highlights – H1’FY21 1 Particulars H1'FY20 H1'FY21 YoY (%) LSI revenue at Rs 1,520 Crore vs Rs 1,559 Crore in H1’FY21 Revenue 1,559 1,520 (2%) Specialty Intermediates 539 515 (4%) EBITDA at Rs 263 Crore up 23% YoY with margin of 17.3% as Nutritional Products 250 274 10% compared to 1
Slide 19: Drug Discovery & Development Solutions – H1'FY21
Drug Discovery & Development Solutions – H1’FY21 DDDS segment revenue up 21% YoY to Rs 132 Crore led by Particulars1 H1'FY20 H1'FY21 YoY (%) growth in Drug Discovery Services business which was driven Revenue 109 132 21% by higher demand from Biotech companies for Integrated Reported EBITDA 30 38
Slide 20: Debt Profile
Debt Profile Particulars 31-Mar-20 30-Jun-20 30-Sep-20 Foreign Currency Loans (US$ m) (US$ m) (US$ m) Subsidiaries 431 435 435 Total 431 435 435 Rupee Loans (Rs Crore) (Rs Crore) (Rs Crore) Standalone 1,295 985 820 Subsidiaries 100 160 125 Total 1,395 1,145 945 Gross Debt (Rs Crore) (Rs Crore) (Rs C
Slide 21: Business outlook
Business outlook We continue to see improvement in demand in most of our business segments be it Specialty Pharma, CMO, API or Specialty Intermediates Given the strong demand recovery and new business sign-ups, we believe COVID-19 is not likely to have a material impact on our overall performanc
Slide 22: Appendix
Ww Mirescncts Appendix 21
Slide 23: Income Statement – Q2 & H1'FY21
Income Statement – Q2 & H1’FY21 Particulars1 Q2'FY20 Q2'FY21 YoY (%) H1'FY20 H1'FY21 YoY (%) Total Revenue from Operations 2,266 2,375 5% 4,448 4,268 (4%) Pharmaceuticals 1,452 1,516 4% 2,781 2,612 (6%) Life Science Ingredients 753 784 4% 1,559 1,520 (2%) Drug Discovery & Development Solutions 61 75
Slide 24: For more information
For more information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002| 21 Ph: +91 22 6645 1209 E-mail: hemant.bakhru@jubl.com E-mail: siddharth@cdr-india.com pavleen.taneja@jubl.com For Media: Sudhakar Safaya Clayton Dsou